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Alteration of the intestinal 
microbiome characterizes 
preclinical inflammatory arthritis in 
mice and its modulation attenuates 
established arthritis
Rebecca Rogier1, Heather Evans-Marin2, Julia Manasson2, Peter M. van der Kraan1, Birgitte 
Walgreen1, Monique M. Helsen1, Liduine A. van den Bersselaar1, Fons A. van de Loo1, Peter L. 
van Lent1, Steven B. Abramson2, Wim B. van den Berg1, Marije I. Koenders1, Jose U. Scher2 & 
Shahla Abdollahi-Roodsaz1,2
Perturbations of the intestinal microbiome have been observed in patients with new-onset and chronic 
autoimmune inflammatory arthritis. However, it is currently unknown whether these alterations 
precede the development of arthritis or are rather a consequence of disease. Modulation of intestinal 
microbiota by oral antibiotics or germ-free condition can prevent arthritis in mice. Yet, the therapeutic 
potential of modulation of the microbiota after the onset of arthritis is not well characterized. We here 
show that the intestinal microbial community undergoes marked changes in the preclinical phase of 
collagen induced arthritis (CIA). The abundance of the phylum Bacteroidetes, specifically families S24-7 
and Bacteroidaceae was reduced, whereas Firmicutes and Proteobacteria, such as Ruminococcaceae, 
Lachnospiraceae and Desulfovibrinocaceae, were expanded during the immune-priming phase of 
arthritis. In addition, we found that the abundance of lamina propria Th17, but not Th1, cells is highly 
correlated with the severity of arthritis. Elimination of the intestinal microbiota during established 
arthritis specifically reduced intestinal Th17 cells and attenuated arthritis. These effects were associated 
with reduced serum amyloid A expression in ileum and synovial tissue. Our observations suggest that 
intestinal microbiota perturbations precede arthritis, and that modulation of the intestinal microbiota 
after the onset of arthritis may offer therapeutic opportunities.
Commensal intestinal microbiota have been implicated in several autoimmune diseases including psoriasis, psori-
atic arthritis (PsA) and rheumatoid arthritis (RA)1,2. PsA and RA are systemic autoimmune diseases characterized 
by chronic joint inflammation and progressive damage to bone and cartilage. Although their exact etiologies are 
unknown, both diseases are considered multifactorial and driven by a combination of genetic and environmental 
factors3,4. Several recent studies have shown that the composition of intestinal microbiota is perturbed in patients 
with recent-onset PsA5 and new-onset as well as chronic RA6–9. PsA microbiota is characterized by a significant 
reduction in Akkermansia, Ruminococcus, and Pseudobutyrivibrio5. Two studies in patients with new-onset RA 
have reported significant expansion of Prevotella copri prior to immunosuppressive treatment6,8. Another study 
found enrichment of Lactobacillus salivarius in RA fecal microbiota, especially during very active disease7. This 
study also found a cluster of metagenomic linkage groups related to Clostridium asparagiforme, Gordonibacter 
pamelaeae, Eggerthella lenta and Lachnospiraceae to be associated with RA with varying duration (3 months 
to >10 years)7. A fourth study in patients with longstanding, treated RA (mean disease duration 81.6 months) 
demonstrated increased abundance of Collinsella, Eggerthella, and Faecalibacterium9. Despite this increasing 
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evidence of the altered microbiota in patients with RA and PsA, it is not clear whether the observed perturbations 
in the intestinal microbiome precede the development of clinical arthritis. Furthermore, the involvement of the 
microbiome and its targetability during ongoing inflammatory arthritis is less well understood.
One of the most prominent effects of microbiota is to define the balance between the pro-inflammatory CD4+ 
T helper 1 (Th1) and Th17 cells and protective regulatory T (Treg) cells, both at mucosal surfaces and systemi-
cally10,11. Th17 cells are considered to play a pathogenic role in PsA and RA by producing several proinflamma-
tory cytokines such as interleukin-17 (IL-17), granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
tumor-necrosis factor (TNFα)12–16. Blockade of IL-17A and its receptor is highly efficacious in the treatment of 
PsA17,18 and, despite lack of robust efficacy in RA, can induce sustained American College of Rheumatology 50 
(ACR50) response in a subset of patients with RA19–21. Th17 cells also induce the production of IL-6, IL-8 and 
tissue-destructive matrix metalloproteinases by other cells such as macrophages and fibroblasts13,22–25. Therefore, 
modulation of the intestinal microbiome may suppress inflammatory arthritis by reducing Th17 cells and multi-
ple Th17-related related proinflammatory mediators.
Several studies have investigated the role of intestinal microbiota in the onset of inflammatory arthritis in 
mouse models. Independent lines of evidence have demonstrated that the development of spontaneous arthri-
tis in SKG, K/BxN and IL-1 receptor antagonist deficient (IL-1Ra−/−) mice is abrogated under germ-free (GF) 
conditions26–28. Colonization of GF K/BxN mice with segmented filamentous bacteria (SFB) reinstated Th17 cell 
differentiation and the production of disease-inducing autoantibodies, and accelerated the onset of arthritis28. It 
was recently shown that SFB stimulate Th17 differentiation via induction of serum amyloid A (SAA) 1 and SAA2 
production by intestinal epithelial cells29,30. IL-22 secretion by type 3 innate lymphoid cells (ILC3) was shown 
to be essential for SAA production by intestinal epithelial cells30. In addition, it was shown that inoculating GF 
arthritis-prone SKG mice with Prevotella-dominated microbiota of RA patients resulted in increased numbers of 
intestinal Th17 cells and enhanced the development of arthritis compared with mice receiving fecal microbiota 
from healthy controls8.
Importantly, depletion of intestinal microbiota with broad-spectrum antibiotics before the induction of 
antigen-induced arthritis and experimental autoimmune encephalomyelitis reduced disease severity31,32. A recent 
study showed that colonizing mice with the human gut commensal Prevotella histicola suppressed Th17 responses 
and the development of inflammatory arthritis in mice33. These observations suggest that microbiota-induced 
modulation of Th17 cell differentiation affects the initial development of inflammatory arthritis in mice. However, 
the role of the intestinal microbiota in the progression of established arthritis and the involved processes are 
unknown.
Using high-throughput sequencing of bacterial 16S rRNA, we here show that marked changes in the intestinal 
microbiota occur in the preclinical phase of inflammatory arthritis and precede the onset of the disease in mice. 
In addition, we show that modulation of intestinal microbiota during ongoing CIA alters both intestinal and 
joint-adjacent T cell profiles associated with changes in SAA and IL-22 expression, and can serve as a potential 
means to control the progression of established inflammatory arthritis.
Results
Altered composition of intestinal microbiota marks the preclinical phase of CIA and precedes 
the development of arthritis. To examine whether perturbations of intestinal microbiota precede or 
rather result from the inflammatory arthritis, we analyzed the intestinal microbiota of naïve DBA1/J mice before 
immunization with collagen type II (CII) and 21 days later prior to the booster injection using microbial 16S 
rRNA sequencing. Mice showed no macroscopic or histological signs of arthritis 21 days after immunization 
confirming the preclinical state (Supplementary Fig. S1A). We did not observe any significant changes in the 
number of operation taxonomic units (OTUs), the rarefaction curves of Chao1 index of bacterial richness, and 
the phylogenetic distance whole tree, a diversity metric based on both the number of observed OTUs and their 
phylogenetic distance (data not shown). Therefore, induction of CIA did not affect the intestinal bacterial rich-
ness and diversity. However, the preclinical, immune-priming phase of CIA was accompanied by marked com-
positional changes in intestinal microbiota at different taxonomic depths from phylum to genus. Analysis of the 
relative abundances at phylum level showed that the intestinal microbiota of naïve mice is dominated by the 
phylum Bacteroidetes (Fig. 1A,B). Comparison of the microbiota of naïve vs. immunized mice revealed that 
phylum Firmicutes dominates the intestinal microbiota in the preclinical phase of arthritis, during which the 
relative abundance of Bacteroidetes decreases (Fig. 1A–C). In addition, the relative abundance of Proteobacteria 
significantly increased after CIA immunization (Fig. 1D).
At the family level, we found that the families S24-7, Bacteroidaceae and Paraprevotellaceae in the phy-
lum Bacteroidetes were significantly reduced in the immune-priming phase of CIA (Fig. 2A–D). Among 
Firmicutes, the families Lachnospiraceae and Ruminococcaceae were expanded while Lactobacillaceae and 
Erysipelotrichaceae were reduced during the preclinical phase of arthritis (Fig. 2A,E–H). Furthermore, the 
family Desulfovibrionaceae in the phylum Proteobacteria was significantly increased in immunized compared 
with naïve mice (Fig. 2I). After correction for multiple testing using the Benjamini-Hochberg procedure, we 
observed a significant increase in the relative abundance of the genera Oscillospira and Ruminococcus (both in 
Ruminococcaceae family) and a significant decrease in Bacteroides (family Bacteroidaceae), Prevotella (family 
Paraprevotellaceae), and Lactobacillus (family Lactobacillaceae) (Supplementary Fig. S2). Only a few OTUs 
could be assigned at the species level, including two OTUs assigned to Lactobacillus reuteri that were significantly 
reduced, and two OTUs aligned to the species Ruminococcus gnavus that were significantly increased in preclini-
cal phase of CIA (Supplementary Table S1). Altogether, our data strongly suggest that alterations of the intestinal 
microbiota occur in the preclinical, induction phase of inflammatory arthritis and likely precede the clinical 
manifestations of the disease.
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Immunization with type II collagen results in increased serum SAA levels and local Th17 cell 
frequency in the preclinical phase of arthritis. As mentioned earlier, no signs of arthritis could be 
observed on macroscopic or histological level (Supplementary Fig. S1A). Serum amyloid A (SAA) has been 
shown to be upregulated at early stages of inflammatory arthritis. Therefore, we measured SAA protein levels in 
serum along with the gene expression of SAA isoforms in the synovium of naïve mice in comparison with immu-
nized mice at day 21 post-immunization before the onset of arthritis. SAA levels in serum showed a significant 
increase 21 days after immunization before the onset of arthritis compared to naïve condition (Supplementary 
Fig. S1B). In addition, we observed a non-significant increase of SAA3 expression in the knee synovial tissue 
(p = 0.2345). However, SAA1 and SAA2 were expressed at low levels and remained similar to the naïve condition 
(Supplementary Fig. S1C). In addition, we analyzed alterations of the T helper cell response in joint-draining 
lymph nodes in the pre-clinical phase of CIA. Flow cytometry analysis showed that the percentage of Th17 cells 
was significantly higher in immunized (preclinical) mice compared to naïve mice (Supplementary Fig. S1D). The 
percentages Th1 and Treg cells and the absolute numbers of Th1, Th17 and Treg cells were not affected by immu-
nization (Supplementary Fig. S1A and E). These data suggest that immune activation characterized by increase in 
SAA serum levels and local Th17 activation precedes the development of CIA.
Treatment with broad-spectrum antibiotics results in partial elimination and compositional 
shifts in the intestinal microbiota of CIA mice. GF condition and elimination of microbiota before the 
induction of arthritis affects the intestinal T cell balance and initiation of arthritis26–28,32. To examine whether 
the gut microbiota modulate T cell responses and disease progression during established arthritis, we treated 
mice with ongoing CIA with broad-spectrum antibiotics (ABX) previously shown to alter the abundance and 
composition of intestinal bacteria in naïve mice31,34. To determine the effects of antibiotic-treatment dur-
ing CIA on the intestinal microbiota, we analyzed bacterial 16S rRNA sequences of ABX-treated and control 
CIA mice. Antibiotic treatment strongly reduced the number of 16S sequence reads compared with the con-
trol treatment (mean of 9002 ± 2167 versus 29392 ± 1140 reads, respectively; p = 0.004). In addition, antibiotic 
treatment resulted in reduced diversity and a marked compositional shift in the remaining intestinal bacterial 
communities of the CIA mice (Supplementary Fig. S3). Specifically, almost all bacteria belonging to the phylum 
Bacteroidetes were eliminated (similar to response in humans35), and the majority of the bacteria that remained 
after antibiotic treatment belonged to the phylum Firmicutes (Supplementary Fig. S3A). The relative abundances 
of intestinal bacterial taxa of the control and antibiotic-treated CIA mice at family and genus levels are shown in 
Supplementary Fig. S3B and C.
Since SFB have been reported to trigger the development of autoimmunity in mice28,29,36, we specifically exam-
ined the presence of SFB. We detected SFB (family Clostridiaceae; genus Candidatus Arthromitus) in the 16S 
sequences of only 2 out of 10 CIA mice before the ABX-treatment. After treatment SFB 16S sequences were 
detectable in 2 out of 5 untreated control mice but none of the ABX-treated mice. Using SFB-specific primers for 
qPCR37, we could confirm the presence of SFB in all cages of CIA mice before the start of antibiotic treatment. At 
the end point, while we could still detect SFB in the untreated control group of CIA mice (Ct ≥ 32), SFB were not 
detectable in any of the ABX-treated CIA mice (data not shown).
Figure 1. Altered composition of fecal microbiota after immunization with type II collagen. (A–D) 16S 
sequencing of fecal microbiota of naïve DBA mice just before immunization with type II collagen compared 
with microbiota of mice 21 days post-immunization before the booster injection and arthritis development. 
Relative abundances of bacterial taxa on phylum level is shown (N = 7 mice per group). Data are shown as 
mean + SEM. **p < 0.01, ***p < 0.001 by Mann-Whitney test followed by a correction for multiple testing 
using the Benjamini-Hochberg procedure.
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Partial elimination of intestinal microbiota during ongoing CIA suppresses proinflammatory T 
helper cell subsets in intestinal lamina propria. It has been described that partial depletion of intestinal 
microbiota in naïve mice results in reduced production of interferon γ (IFNγ) and IL-17 by mucosal CD4+ T cells 
in small intestine lamina propria (LP)34. Therefore, we investigated whether depletion of intestinal microbiota 
during CIA affects the intestinal T helper cell balance. Flow cytometry analysis revealed a slight, non-significant 
reduction in the proportion of TCRβ+CD4+ T helper cells in intestinal LP after ABX treatment (p = 0.06, 
Fig. 3A,B). Antibiotic treatment resulted in a specific reduction in the percentage of TCRβ+CD4+IL-17+ Th17 
cells in LP of mice with CIA (p = 0.004, Fig. 3A and C), similar to previously published observations in naïve 
mice34. In addition, a reduction in TCRβ+CD4+IFNγ+ Th1 cells was observed after ABX treatment; however, 
Figure 2. Intestinal microbiota undergoes marked changes in the preclinical phase of arthritis. (A) 16S 
sequencing of fecal microbiota of naïve DBA mice just before immunization with type II collagen compared 
with microbiota of mice day 21 post-immunization and before the booster injection. Relative abundances on 
family level is shown, however part of the bacteria could not be classified further than order-level, taxonomic 
level is indicated, o = order and f = family. (B–I) Relative abundances of intestinal bacteria at family level. N = 7 
mice per group. Data are shown as mean + SEM. **p < 0.01, ***p < 0.001 by Mann-Whitney test followed by 
correction for multiple testing using the Benjamini-Hochberg procedure.
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this effect was heterogeneous and did not reach statistical significance (p = 0.1059, Fig. 3A and C). In contrast, 
ABX treatment did not affect the proportion of TCRβ+CD4+Foxp3+ Treg cells in the intestinal LP of CIA mice 
(Fig. 3C).
Next, we analyzed cytokine production by LP lymphocytes (LPLs) stimulated ex vivo with PMA and ion-
omycin. In accordance with the flow cytometry data, IL-17 production was significantly reduced in LPLs of 
ABX-treated mice compared with control mice (Fig. 3D). IL-4 showed a trend towards reduction (p = 0.0892; 
Supplementary Fig. S4A), while the production of IFNγ and IL-10 remained unaffected (p = 0.2428 and 
p = 0.9705, respectively; Fig. 3E and Supplementary Fig. S4B). Analysis of the gene expression showed that 
ABX treatment significantly reduced expression of IL-17A mRNA in terminal ileum (p = 0.008), a main site for 
microbiota-induced T cell modulation, whereas the expression IFNγ and IL-10 mRNA was not affected signif-
icantly (Supplementary Fig. S4C). The expression of IL-17, IFNγ and IL-10 in colon tissue was not affected by 
antibiotic treatment (Supplementary Fig. S4D) In addition, while unaffected in small intestine, the expression 
of the Treg-related transcription factor FoxP3 was significantly upregulated in the colon of ABX-treated mice 
(Supplementary Fig. S4E). Altogether, these observations indicate that partial elimination of intestinal microbiota 
during established CIA modulates the mucosal T helper cell balance mainly presented by a suppression of Th17 
cells.
Antibiotic treatment reduces intestinal SAA1 and SAA2 expression in CIA mice. The mechanism 
of microbiota-induced Th17 cell differentiation in intestinal LP was reported for SFB as model organisms. It was 
demonstrated that SFB-induced intestinal epithelial production of SAA1 and SAA2 in terminal ileum, stimulated 
Figure 3. Treatment with broad-spectrum antibiotics during established CIA skews the intestinal T helper cell 
balance. (A) Representative flow cytometry plots showing the percentage of Th1 and Th17 cells per gate. (B) 
Percentage of CD4+TCRβ+ Th cells of viable cells isolated from the intestinal lamina propria. (C) Percentage 
of IL-17+ (Th17), IFNγ+ (Th1) and FoxP3+ (Treg) cells among CD4+TCRβ+ cells isolated from intestinal 
lamina propria. (D,E) Production of IL-17 and IFNγ by lamina propria lymphocytes upon ex vivo stimulation 
with PMA and ionomycin for 5 hours, measured by Luminex cytokine array. (A–E) Cells were isolated from 
untreated control (Ctrl, n = 12) and antibiotic-treated (ABX, n = 10) mice at the end of the antibiotic treatment. 
(F,G) Gene expression of serum amyloid A (SAA) 1, 2 and 3 (F) and IL-22 (G) in terminal ileum of small 
intestine. Gene expression was measured by qPCR in tissues from Ctrl (n = 18) and ABX (n = 19) mice. Relative 
mRNA expression is shown as 2−ΔCt *10000, corrected for GAPDH. Data are shown as mean + SEM. *p < 0.05, 
**p < 0.01, ***p < 0.001 by Mann-Whitney test; N.S. not significant.
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by ILC3-derived IL-22, is required for the functional differentiation of Th17 cells and the production of IL-1730. 
Therefore, we analyzed the expression of SAA1, SAA2 and SAA3 isoforms as well as IL-22 in terminal ileum. In 
line with the reduction of Th17 cell abundance in LP upon ABX treatment (Fig. 3A and C), both SAA1 and SAA2 
were markedly diminished in terminal ileum of ABX-treated CIA mice compared with the control CIA mice 
(Fig. 3F). However, SAA3 expression was lower than SAA1 and SAA2, and showed a non-significant reduction 
(Fig. 3F). Furthermore, while IL-22 was detectable in the majority of control CIA mice (15 out of 18), its expres-
sion was markedly attenuated in ABX-treated CIA mice and was detectable only in 2 out of 19 mice (Fig. 3G). This 
suggests that reduced Th17 cell differentiation and IL-17 production in ABX-treated CIA mice may have resulted 
from lower IL-22-mediated induction of SAA1 and SAA2 due to the elimination of commensal microbiota.
Elimination of intestinal microbiota reduces the severity of established T cell-mediated exper-
imental arthritis. We monitored the severity of arthritis in control and antibiotic-treated CIA mice. ABX 
treatment significantly attenuated the severity of established arthritis in CIA mice (Fig. 4A). Interestingly, the 
abundance of Th17 cells in the intestinal LP of CIA mice showed a striking correlation with the severity of arthritis 
(r = 0.666; p = 0.001), while no correlation was found between the LP Th1 cells and arthritis (Fig. 4B and C). This 
supports the presence of a potentially relevant link between the microbiota-induced intestinal Th17 cells and the 
severity of experimental arthritis. Importantly, the numbers of Th17 and Th1 cells in joint-draining pLN were sig-
nificantly reduced in ABX-treated CIA mice compared with control mice (Fig. 4D). Accordingly, pLN cells from 
ABX-treated mice produced less IL-17 (p = 0.0392) upon ex vivo stimulation with PMA and ionomycin (Fig. 4E). 
The release of IFNγ in ex vivo LPL cultures was not significantly affected by the ABX treatment (p = 0.3390, 
Figure 4. Elimination of intestinal microbiota reduces the severity of established T cell-mediated experimental 
arthritis. (A) Arthritis severity scores of untreated control (Ctrl) and antibiotic-treated (ABX) CIA mice; 
n = 19 mice per group from two independent experiments. Severity was scored on a scale of 0–2 for each paw. 
**p < 0.01 by two-tailed Mann-Whitney U test. (B,C) Correlation between the percentages of Th17 and Th1 
cells in the intestinal lamina propria and arthritis severity scores of mice with CIA. The Spearman’s correlation 
coefficient (r) and the p value are shown at the top left of the graphs. (D) Number of Th17 (CD4+TCRβ+ 
IL-17+) and Th1 (CD4+TCRβ+IFNγ+) cells isolated from popliteal lymph nodes (pLN) of Ctrl (n = 11) and 
ABX-treated (n = 10) CIA mice. (E,F) Concentration of IL-17 and IFNγ in culture supernatants of pLN cells 
from Ctrl (n = 12) and (n = 11) ABX mice ex vivo stimulated with PMA and ionomycin for 5 hours. (G) Gene 
expression of SAA1, SAA2 and SAA3 in synovial biopsies of Ctrl (n = 12) and ABX (n = 13) mice. Relative 
mRNA expression is shown as 2−ΔCt *10000, corrected for GAPDH. (D–G) Data are shown as mean + SEM. 
*p < 0.05, **p < 0.01 by Mann-Whitney test.
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Fig. 4F). Furthermore, the production of IL-10 and IL-4 remained unaffected (p = 0.5179 and p = 0.4417 respec-
tively, data not shown). These observations suggest that partial elimination of intestinal microbiota after the 
onset of arthritis, i.e. during established CIA, attenuates the disease and is associated with a parallel reduction 
in IL-17 production in joint-draining lymph nodes and intestinal LP. We further assessed the expression of the 
SAA isoforms in synovial tissue. In contrast to terminal ileum, SAA3 was the major isoform in the synovium 
and its expression was strongly decreased in antibiotic-treated CIA mice (p = 0.0180, Fig. 4G). Furthermore, 
reduced joint inflammation in antibiotic-treated CIA mice was accompanied by a significant suppression of SAA1 
(p = 0.0471) and a non-significant reduction of SAA2 (p = 0.0771) mRNA expression in synovial tissue (Fig. 4G).
Interestingly, while both LP and pLN Th17 cells were affected, we could not find any difference in serum lev-
els of anti-mouse collagen type II auto-antibodies between the control and ABX-treated mice (Supplementary 
Fig. S5). Therefore, the observed reduction in CIA disease severity by post-onset antibiotic treatment is not asso-
ciated with a suppression of CII-specific antibody response.
In addition, elimination of intestinal microbiota by the ABX treatment was unable to modulate the severity of 
serum-transfer arthritis, a T cell-independent model38,39 induced by the transfer of arthritogenic K/BxN serum 
(Supplementary Fig. S6). These data suggest that elimination of intestinal microbiota during T cell-mediated 
experimental arthritis can attenuate Th17-driven disease processes, whereas arthritis induced by the already gen-
erated arthritogenic antibodies does not depend on the intestinal microbiota.
Discussion
Several studies have shown that the composition of intestinal microbiota is perturbed in patients with inflam-
matory arthritis such as new-onset as well as chronic RA5–7,9,40. The development of autoimmunity in RA starts 
several years before the appearance of the clinical signs, a process that commensal microbiota may be able to 
promote41–43. Therefore, it is important to understand whether the observed perturbations in the intestinal micro-
biota precede the onset of inflammatory arthritis or are merely a consequence of disease. While this remains to be 
determined in humans at-risk of developing inflammatory arthritis, we here show that in experimental arthritis, 
marked changes in the intestinal microbiota occur in the preclinical immune-priming phase and precede the 
onset of inflammatory arthritis. A recent study showed that the composition of microbiota prior to arthritis onset 
differs between the CIA–susceptible and –resistant mice44. This study found that the family Lactobacillaceae 
was more abundant in CIA-susceptible mice, whereas Desulfovibrionaceae and Lachnospiraceae were more 
abundant in CIA–resistant mice44. Moreover, by comparing the fecal bacterial composition in the immunized 
mice before and after the onset of arthritis, it was shown that the families Bacteroidaceae, Lachnospiraceae and 
S24-7 significantly increased as arthritis initiated44. Our studies focused on the preclinical phase of arthritis and 
show that this phase is characterized by decreased S24-7 and Bacteroidaceae and increased Ruminococcaceae, 
Lachnospiraceae and Desulfovibrinocaceae. Increased Lachnospiraceae has previously also been demonstrated 
in RA patients with varying disease duration7. Our data demonstrate that the increase in Lachnospiraceae occurs 
before the onset of arthritis and is induced by the immunization during the preclinical phase. Another study com-
pared the microbiome of healthy non-immunized mice and mice with CIA. This study found that Clostridiales, 
Lachnospiraceae and Ruminoccocus gnavus were more abundant in the mice with established CIA compared to 
the healthy mice45. Interestingly, we found these taxa to be increased in the preclinical phase and before the onset 
of arthritis. Altogether, these observations suggest that early perturbations of the intestinal microbiota during the 
immune-priming phase may contribute to the initiation of inflammatory arthritis.
We previously showed that treatment with Tobramycin resulted in a near-complete elimination of the gen-
era Helicobacter and Flexispira (both belonging to the family Helicobacteraceae) and suppressed arthritis in 
IL-1Ra-deficient mice46. In addition, a strong and highly significant reduction in the genus Clostridium was 
observed, which suggests that these bacteria may promote intestinal Th17 cell differentiation and arthritis46. In 
the present study, we observed a strong and significant increase in the order Clostridiales after immunization with 
collagen. However, a large part of the order Clostridiales could not be assigned to a higher taxonomic level and 
the exact effects on the genus Clostridium remain to be clarified.
Previous studies showed that Prevotella copri is expanded in patients with new-onset RA6,8. In addition, it was 
shown that transfer of Prevotella-dominated microbiota of RA patients to SKG mice results in increased numbers 
of intestinal Th17 cells and exacerbates arthritis compared with mice receiving fecal microbiota from healthy 
controls8. Identification of the exact Prevotella species altered upon immunization in CIA mice was not possible 
using 16S rRNA gene sequencing due to inherently limited resolution of this technique. Furthermore, none of 
the observed OTUs related to Prevotella in our database could be assigned to P. copri. Therefore, we performed P. 
copri-specific qPCR using species specific primers6 to detect P. copri with a higher sensitivity (primer sequences in 
Suppl. Table S2). While our positive control (DNA isolated from anaerobically grown P. copri) showed a positive 
signal on qPCR with a Ct value of 17.7 cycles, P. copri DNA was detected at very low levels (Ct value of >33 cycles) 
in fecal DNA of the mice and was not different between naïve and immunized mice. Therefore, the abundance of 
P. Copri was not altered in our mice by CII immunization.
Loss of intestinal microbial diversity and richness coincides with autoimmune diseases such as diabetes, RA 
and PsA in patients5,6,47. Our data suggest that the preclinical phase of experimental arthritis is not accompanied 
by significant changes in the microbial diversity and richness. It is tempting to speculate that the reduced micro-
bial diversity reported in human autoimmune disease may be a consequence of the ongoing inflammation at the 
time of sampling. While our study was able to identify robust changes in the intestinal microbiota that precede the 
onset of inflammatory arthritis, it is important to expand and strengthen such studies with shotgun sequencing 
coupled with transcriptomics and metabolomics approaches to understand the full functional capacity of the 
microbiome during the preclinical phase of arthritis. More importantly, similar studies are warranted in humans 
at risk of developing autoimmune arthritis before the onset of inflammation to unravel the relevance of the micro-
biome in predisposition or the inductive phase of the disease.
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Intestinal LP is a major source of Th17 cells in the body29,48. Previous studies have shown that alterations of 
the gut commensal bacteria have strong effects on Th17 cell differentiation29,48. Commensal microbiota have 
been shown to promote the initiation of spontaneous arthritis in IL-1Ra−/− mice as well as in K/BxN mice, which 
bear a transgenic auto-reactive T cell receptor27,28. In non-transgenic animal models, treatment with a cocktail of 
vancomycin, neomycin and metronidazole before the induction of antigen-induced arthritis resulted in milder 
disease32. On the other hand, gut microbiota-induced IL-1 and IL-6 can trigger the respective cytokine receptors 
on B cells to promote differentiation of IL-10-producing regulatory B cells and restrict antigen-induced arthritis32. 
However, it is not clear whether modulation of intestinal microbiota after the onset of arthritis can still alter the T 
cell phenotype and modify the progression of arthritis.
In this study, we employed a widely-used model of inflammatory arthritis induced in non-transgenic mice 
to assess the role of intestinal microbiota during already established disease. We show here for the first time that 
elimination of intestinal microbiota during established CIA attenuates inflammatory arthritis. This is in line with 
earlier reports that oral antibiotic treatments with sulfasalazine and minocycline reduce RA disease activity in 
patients with disease duration of <1 year49,50. Elimination of microbiota after the onset of arthritis resulted in sup-
pression of intestinal SAA1, SAA2 and IL-22 expression and a specific reduction of LP Th17 cells accompanied 
with reduced Th17 cell abundance in joint-draining lymph nodes of the CIA mice. The potential of intestinal T 
cells to migrate to peripheral lymph nodes, as reported before, may explain these observations51. Our data also 
show for the first time a direct correlation between the abundance of LP Th17 cells and the severity of arthritis, 
which further supports a continued pro-inflammatory gut-joint axis during established arthritis.
Previous studies identified SFB as potent inducers of Th17 cell differentiation promoting arthritis develop-
ment in the T cell-mediated K/BxN model28,29. Elimination of SFB by ABX treatment in our study is consistent 
with reduced LP Th17 cells and suppressed expression of SAA1 and SAA2, which were recently reported to act 
on Th17 cells to further enhance their differentiation and effector function30. Our data suggest that the observed 
Th17 cell reduction upon antibiotic treatment in our study is at least partially due to the elimination of SFB, 
although the effect of other microbiota cannot be excluded. Interestingly, although SAA1 and SAA2 were the 
most abundant SAA isoforms in the intestine, SAA3 appeared to be the prominent isoform in the target tissue, 
i.e. synovium, and its expression was similarly affected by the microbiota. While SAA1/SAA2 were shown to 
promote intestinal Th17 cells, it is not known if SAA has a similar effect on Th17 cells residing in the synovium. 
Several studies have shown the relevance of SAA as a marker of RA disease activity and its association with 
disease-relevant autoantibodies and acute phase proteins52–55. In addition, several RA therapies have been shown 
to influence circulating SAA levels during treatment52–55. Furthermore, SAA is also a good indicator of cardiovas-
cular and renal involvement in patients with RA56. Besides being a valuable marker for disease activity, SAA has 
been shown to mediate inflammatory and angiogenic mechanisms, likely through TLR257,58. Our data demon-
strate that increased systemic level of SAA precedes the onset of arthritis and can be used as a disease marker even 
before its clinical onset.
In line with the essential role of IL-22 in intestinal SAA production30, we observed a significant reduction of 
intestinal IL-22 expression after antibiotic treatment. IL-22 was shown to be highly expressed in synovium of RA 
patients and serum levels of IL-22 are significantly higher in RA patients compared with healthy controls and 
correlate with disease activity59,60. In addition, elevated levels of IL-22 in early disease seem to predict erosive pro-
gression, suggesting that IL-22 has a role in the pathophysiology of RA61. In patients with PsA, IL-22-producing 
CD4+ T cells were increased in peripheral blood as well; however, IL-22-positive cells could not be detected in 
synovial fluid and tissue of PsA patients62.
Although our studies support suppression of intestinal and joint-adjacent Th17 differentiation as an 
underlying mechanism for attenuation of arthritis upon elimination of intestinal microbiota, involvement of 
microbiota-induced regulation of other immune cells is not excluded. In this regard, a recent study showed that 
continuous treatment with ampicillin and vancomycin limited follicular T helper (Tfh) cell differentiation and 
germinal center formation in K/BxN mice, resulting in reduced production of arthritogenic autoantibodies and 
less severe arthritis63. These effects appeared to be independent of IL-17, which was found to be dispensable 
for the disease development in this study, although an earlier study showed that IL-17 blockade could reduce 
anti-GPI antibody levels and suppress K/BxN arthritis28,63. We observed no effect of ABX treatment on serum 
levels of anti-mouse collagen type II antibodies in our experiments, suggesting that during ongoing CIA, intes-
tinal microbiota affect Th17 cell differentiation and arthritis without influencing the autoantibody response. 
Therefore, intestinal microbiota appear to influence different disease mechanisms depending on the disease phase 
and processes being studied. In addition, by mimicking the effector phase of the K/BxN arthritis using KRN 
serum-transfer model, we show that intestinal microbiota do not play an important role in K/BxN arthritis any-
more once the disease-inducing auto-antibodies have been developed (Supplementary Fig. S6).
In agreement with our findings, IL-17 producing T cells can promote arthritis independent of their influence 
on antibody production, since transfer of IL-17-producing KRN transgenic T cells into a B-cell-deficient host 
can enhance arthritis in an IL-17-dependent manner64. In fact, Th17 cells contribute to several pro-inflammatory 
and tissue-destructive processes during inflammatory arthritis and may represent a relevant target to control 
the disease12,13. The role of Th17 cells in arthritis is likely to expand beyond its prototypic cytokine IL-17A. The 
actual requirement of Th17 cells for the microbiota-induced aggravation of arthritis requires, however, further 
investigation.
It has been described that Th17 cells can transition into a stage in which they produce both IL-17 and IFNγ, 
after which they may lose their expression of IL-1765. A recent study showed that these IFNγ-producing cells, 
called ex-Th17 cells or non-classical Th1 cells, are not constrained by regulatory T cells66. In addition, these cells 
were shown to accumulate in arthritic joint of arthritis patients66, suggesting a role in the pathogenesis of RA. 
We analyzed the proportions of IL-17+ IFNγ+ double-positive TCRβ+CD4+ cells. We observed a non-significant 
reduction in the percentage, but not absolute number, of IL-17+ IFNγ+ TCRβ+CD4+ in intestinal lamina propria 
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by antibiotic treatment (Mean ± SEM of control: 1.049% ± 0.2594; ABX: 0.4699% ± 0.1297). Furthermore, 
while there was no significant effect of antibiotic treatment on the percentage of IL-17+ IFNγ+ TCRβ+CD4+ 
cells in pLNs, we observed a non-significant reduction in the numbers of these cells (Ctrl: 537.9 ± 228.6; ABX: 
240.6 ± 76.38). We cannot exclude the possibility that the Th1 cells, which were significantly reduced in pLNs 
after ABX-treatment, also included exTh17 cells only producing IFNγ.
Multiple studies showed that Th17 levels are high in treatment-naïve patients with early RA67–69. While ele-
vated levels of Th17 cells have been found in RA and PsA patients, reports on the proportion of Th17 cells in 
patients with established RA are inconsistent62,67,70–75. Based on the higher efficacy of IL-17 blockade in PsA com-
pared with RA, it is plausible that the PsA microbiome has a higher potential to induce mucosal Th17 and IL-17 
responses. On the other hand, it is possible that stratification of patients with RA based on their gut microbiota 
and its Th17-inducing potential improves the efficacy of IL-17 inhibition in RA. A side-by-side comparison of 
matched cohorts of PsA and RA patients will be required to address the exact differences between RA and PsA 
microbiomes and their relevance for the efficacy of biologic treatments.
In summary, our study suggests that perturbations in the intestinal microbiota precede the onset of arthritis. 
In addition, we show that elimination of intestinal microbiota during established CIA reduces Th17 cell abun-
dance in intestinal mucosa and joint-draining lymph nodes and attenuates arthritis without affecting autoan-
tibody production. While our study does not advocate the use of antibiotics as a treatment for RA or related 
inflammatory arthropathies, it supports the notion that inflammatory signals provided by the gut microbiota 
continue to promote arthritis after its onset. The striking correlation between the abundance of intestinal Th17 
cells and the severity of arthritis supports this link. Understanding the exact mechanisms linking the intestinal T 
cell response with arthritis may help identifying novel therapeutic strategies for inflammatory arthritis.
Material and Methods
Mice and induction of CIA. Male DBA/1J mice (Janvier, France) were housed in individually-ventilated 
cages, and water and food were provided ad libitum. CIA was induced by intradermal injection of 100 µg bovine 
type II collagen (CII) in Freund’s complete adjuvant on day 0 and intraperitoneal booster injection of 100 µg CII 
in PBS on day 21. Clinical onset and progression of arthritis was scored on a scale between 0–2 for each paw as 
described before76. All animal studies were approved by the institutional review board (Animal Experimentation 
Committee of Radboud University Medical Center) and were conducted in accordance with the institutional 
guidelines.
Sample collection and DNA extraction. Feces were collected and stored at −80 °C until processing. 
Fecal DNA was collected using the PowerLyzer DNA isolation kit (MO BIO laboratories) following manufactur-
er’s instructions.
16S sequencing of intestinal microbiota. Amplicon library preparation was performed using an auto-
mated platform (Biomek 4000) with a custom liquid handling method. For each sample, the V4 region of the 
bacterial 16S rRNA gene was amplified in duplicate reactions using primer set 515F/806R, which nearly uni-
versally amplifies bacterial and archaeal 16S rRNA genes. Each unique barcoded amplicon was generated in 
pairs of 25 μl reactions with the following reaction conditions: 11 μl PCR-grade H2O, 10 μl Hot MasterMix, 2  μl 
of forward and reverse barcoded primer (5 μM) and 2 μl template DNA. Reactions were run on a C1000 Touch 
Thermal Cycler (Bio-Rad) with the following cycling conditions: initial denaturing at 94 °C for 3 min followed 
by 35 cycles of denaturation at 94 °C for 45 seconds, annealing at 58 °C for 1 minute, and extension at 72 °C for 
90 seconds, with a final extension of 10 minutes at 72 °C. Amplicons were quantified using the Agilent 2200 
TapeStation system and pooled. Purification was then performed using Ampure XT (Beckman Coulter) as per 
the manufacturer instructions. Sequencing was performed using the MiSeq (Illumina) platform to produce 150 
base-pair end reads and define the microbiota composition, as we previously described77. The obtained 16S rRNA 
sequences were analyzed using the Quantitative Insights into Microbial Ecology (QIIME) pipeline for analysis of 
community sequence data. Briefly, reads were demultiplexed and quality filtered with default parameters using 
prinseq. Sequences were then clustered into operational taxonomic units (OTUs) using a 97% similarity thresh-
old with USEARCH and the Greengenes 16S reference dataset and taxonomy78. PyNAST was used as the default 
alignment tool for QIIME.
Antibiotic treatment. CIA mice with a macroscopic score of 0.25–2.75 were randomized for treatment 
with a cocktail of 0.5 g/L vancomycin (Sigma), and 1 g/L metronidazole (Acros Organics), neomycin trisulfate 
(Sigma) and ampicillin sodium salt (Sigma) provided in drinking water containing 6 g/L sucrose for 1 week or for 
the control treatment (only sucrose).
Isolation of lamina propria-lymphocytes (LPLs). Small intestine and colon were isolated and residual 
mesenteric fat and Peyer’s patches were removed. The intestine was opened longitudinally, washed with ice-cold 
PBS and treated twice with 5 mM EDTA for 10 minutes at 37 °C to remove the epithelial cells. The tissue was 
further digested using collagenase D (0.5 mg/ml, Roche), DNase I (0.25 mg/ml, Sigma), and Dispase (50 U/ml, 
Fisher) for 3 cycles of 20 minutes at 37 °C. Cells were passed through a 40 μM cell strainer and LP lymphocytes 
were harvested at the interphase of a 40%/80% Percoll gradient (Sigma).
Induction of K/BxN serum-transfer arthritis. Serum-transfer arthritis was induced in C57Bl/6 mice by 
two intraperitoneal injections of 200 µl arthritogenic serum derived from arthritic K/BxN mice on days 0 and 2, 
as described before79. Mice were treated with antibiotics as described above for CIA starting from day 0 because 
of the acute nature and short span of the serum-transfer model.
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Flow cytometry. Cells were incubated with phorbol 12-myristate 13-acetate (PMA; 50 ng/ml; Sigma), 
ionomycin (1 μg/ml; Sigma), and Brefeldin A (1 μl/ml; BD Biosciences) at 37 °C for 4 hours and stained with 
anti-CD4-APC (Biolegend), anti-TCRβ-FITC (Biolegend) and fixable viability dye (eBioscience). For intracellu-
lar staining, cells were fixed and permeabilized using fixation/permeabilization buffer (eBioscience) and stained 
with anti-IL-17-PECy7 (biolegend), anti-IFNγ-PE (BD pharmingen), and anti-FOXP3-PE (eBioscience) in per-
meabilization buffer (eBioscience). Data were collected on Gallios flow cytometer (Beckman Coulter) and ana-
lyzed with Flowjo 10.0 software.
Cell culture and measurement of cytokines. Popliteal lymph nodes (pLN) were disrupted on a 70 µm 
cell strainer. LPLs (4 × 105 cells/well) and pLN cells (2 × 105 cells/well) were cultured with PMA (50 ng/ml; sigma) 
and ionomycin (1 µg/ml; Sigma) for 6 hours. Cytokine concentrations in culture supernatants and mice sera were 
measured by Luminex using the mouse cytokine/chemokine magnetic bead kits (Bio-Rad).
RNA isolation and quantitative real-time PCR. Tissues were homogenized using a MagNA lyser 
instrument (Roche). RNA was isolated in TRIzol reagent (Sigma) as described before27. Quantitative real-time 
PCR (qRT-PCR) was performed using the StepOne System (Applied Biosystems) using the SYBR green Master 
Mix (Applied Biosystems). Primer sequences are shown in Supplementary Table S2.
Measurement of anti-collagen antibodies. Anti-mouse CII IgG1 and IgG2a antibodies were deter-
mined in serum using ELISA, as reported before80. Briefly, 96 wells plates were coated with 0.1 µg of mouse type 
II collagen (chondrex). Non-specific binding sites were blocked by a 5% solution of milk powder. Serial dilutions 
of mouse sera were added, followed by incubation with peroxidase-labeled isotype-specific goat-anti-mouse-IgG 
antibodies and 5-aminosalicylic acid as substrate. Absorbance was measured at 450 nm.
SAA serum levels. Serum amyloid A in serum was measured with ELISA (R&D systems) according to the 
manufacturer’s guidelines.
Histology. Total ankle joints were isolated and fixed in 4% formaldehyde for 4 days, thereafter decalcified in 
5% formic acid and embedded in paraffin. Tissue sections of 7 μM were stained using hematoxylin and eosin to 
study synovial inflammation, cartilage destruction, and bone erosion.
Statistics. Differences in the relative abundance of bacterial taxa between groups were evaluated using 
Mann-Whitney test. Differences in operational taxonomic units (OTUs) were evaluated using two-tailed Student’s 
t-test. We corrected for multiple testing using the Benjamini and Hochberg procedure with false discovery rate 
(FDR) set at 10%, and differences with a p-value < 0.05 which passed the FDR test were considered statistically 
significant. Mann-Whitney U test was used to compare cell and cytokine levels between treatment groups. For 
arthritis scores, two-tailed Mann-Whitney U test was performed for area under the curve. Correlations were 
examined using Spearman’s rank test. Statistical significance was indicated on figures as follows: *P < 0.05, 
**P < 0.01, ***P < 0.001.
References
 1. Abdollahi-Roodsaz, S., Abramson, S. B. & Scher, J. U. The metabolic role of the gut microbiota in health and rheumatic disease: 
mechanisms and interventions. Nature reviews. Rheumatology 12, 446–455 (2016).
 2. Scher, J. U., Littman, D. R. & Abramson, S. B. Microbiome in Inflammatory Arthritis and Human Rheumatic Diseases. Arthritis & 
rheumatology (Hoboken, N.J.) 68, 35–45 (2016).
 3. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N Engl J Med 365, 2205–2219 (2011).
 4. Schett, G., Coates, L. C., Ash, Z. R., Finzel, S. & Conaghan, P. G. Structural damage in rheumatoid arthritis, psoriatic arthritis, and 
ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis research & 
therapy 13(Suppl 1), S4 (2011).
 5. Scher, J. U. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling 
dysbiosis in inflammatory bowel disease. Arthritis & rheumatology (Hoboken, N.J.) 67, 128–139 (2015).
 6. Scher, J. U. et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife 2, e01202 (2013).
 7. Zhang, X. et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat Med 
21, 895–905 (2015).
 8. Maeda, Y. et al. Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis & 
rheumatology (2016).
 9. Chen, J. et al. An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis. Genome medicine 8, 43 (2016).
 10. Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75–84 (2016).
 11. Kamada, N. & Nunez, G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 146, 1477–1488 
(2014).
 12. Lubberts, E. The IL-23-IL-17 axis in inflammatory arthritis. Nature reviews. Rheumatology 11, 415–429 (2015).
 13. van den Berg, W. B. & McInnes, I. B. Th17 cells and IL-17 a–focus on immunopathogenesis and immunotherapeutics. Semin 
Arthritis Rheum 43, 158–170 (2013).
 14. Avci, A. B., Feist, E. & Burmester, G. R. Targeting GM-CSF in rheumatoid arthritis. Clinical and experimental rheumatology 34, 
39–44 (2016).
 15. Wicks, I. P. & Roberts, A. W. Targeting GM-CSF in inflammatory diseases. Nature reviews. Rheumatology 12, 37–48 (2016).
 16. Tesmer, L. A., Lundy, S. K., Sarkar, S. & Fox, D. A. Th17 cells in human disease. Immunological reviews 223, 87–113 (2008).
 17. Mease, P. J. et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. The New England journal of medicine 370, 
2295–2306 (2014).
 18. Mease, P. J. et al. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med 373, 1329–1339 
(2015).
 19. Genovese, M. C. et al. A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in 
rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. 
Arthritis & rheumatology (Hoboken, N.J.) 66, 1693–1704 (2014).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 7: 15613  | DOI:10.1038/s41598-017-15802-x
 20. Genovese, M. C. et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-
finding, double-blind, randomized, placebo-controlled study. The Journal of rheumatology 41, 414–421 (2014).
 21. Burmester, G. R. et al. Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody 
secukinumab in active rheumatoid arthritis. Rheumatology (Oxford, England) 55, 49–55 (2016).
 22. Koenders, M. I. et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone 
erosion by decreasing RANKL and interleukin-1. Am J Pathol 167, 141–149 (2005).
 23. Sato, K. et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 
203, 2673–2682 (2006).
 24. Kotake, S. et al. IL−17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin 
Invest 103, 1345–1352 (1999).
 25. Hot, A. & Miossec, P. Effects of interleukin (IL)-17A and IL-17F in human rheumatoid arthritis synoviocytes. Annals of the 
rheumatic diseases 70, 727–732 (2011).
 26. Rehaume, L. M. et al. ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and 
ileitis in SKG mice. Arthritis & rheumatology (Hoboken, N.J.) 66, 2780–2792 (2014).
 27. Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. 
J Clin Invest 118, 205–216 (2008).
 28. Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815–827 
(2010).
 29. Ivanov, I. I. et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
 30. Sano, T. et al. An IL-23R/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses. Cell 163, 
381–393 (2015).
 31. Ochoa-Reparaz, J. et al. Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. 
Journal of immunology (Baltimore, Md.: 1950) 183, 6041–6050 (2009).
 32. Rosser, E. C. et al. Regulatory B cells are induced by gut microbiota-driven interleukin-1beta and interleukin-6 production. Nat Med 
20, 1334–1339 (2014).
 33. Marietta, E. V. et al. Human Gut-Derived Prevotella histicola Suppresses Inflammatory Arthritis in Humanized Mice. Arthritis & 
rheumatology (2016).
 34. Hill, D. A. et al. Metagenomic analyses reveal antibiotic-induced temporal and spatial changes in intestinal microbiota with 
associated alterations in immune cell homeostasis. Mucosal Immunol 3, 148–158 (2010).
 35. Isaac, S. et al. Short- and long-term effects of oral vancomycin on the human intestinal microbiota. The Journal of antimicrobial 
chemotherapy 72, 128–136 (2017).
 36. Lee, Y. K., Menezes, J. S., Umesaki, Y. & Mazmanian, S. K. Proinflammatory T-cell responses to gut microbiota promote experimental 
autoimmune encephalomyelitis. Proc Natl Acad Sci USA 108(Suppl 1), 4615–4622 (2011).
 37. Barman, M. et al. Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract. Infect Immun 76, 907–915 
(2008).
 38. Korganow, A. S. et al. From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity 10, 
451–461 (1999).
 39. Kyburz, D. & Corr, M. The KRN mouse model of inflammatory arthritis. Springer Semin Immunopathol 25, 79–90 (2003).
 40. Maeda, Y. et al. Dysbiosis Contributes to Arthritis Development via Activation of Autoreactive T Cells in the Intestine. Arthritis & 
rheumatology (Hoboken, N.J.) 68, 2646–2661 (2016).
 41. van de Stadt, L. A. et al. Development of the anti-citrullinated protein antibody repertoire prior to the onset of rheumatoid arthritis. 
Arthritis and rheumatism 63, 3226–3233 (2011).
 42. Deane, K. D. et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time 
to diagnosis in an age-dependent manner. Arthritis and rheumatism 62, 3161–3172 (2010).
 43. van der Woude, D. et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is 
associated with the disease course of early arthritis. Annals of the rheumatic diseases 69, 1554–1561 (2010).
 44. Liu, X. et al. Role of the Gut Microbiome in Modulating Arthritis Progression in Mice. Scientific reports 6, 30594 (2016).
 45. Ben-Amram, H. et al. Tuftsin-Phosphorylcholine Maintains Normal Gut Microbiota in Collagen Induced Arthritic Mice. Frontiers 
in microbiology 8, 1222 (2017).
 46. Rogier, R. et al. Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent 
arthritis. Microbiome 5, 63 (2017).
 47. Giongo, A. et al. Toward defining the autoimmune microbiome for type 1 diabetes. The ISME journal 5, 82–91 (2011).
 48. Gaboriau-Routhiau, V. et al. The key role of segmented filamentous bacteria in the coordinated maturation of gut helper T cell 
responses. Immunity 31, 677–689 (2009).
 49. Hannonen, P., Mottonen, T., Hakola, M. & Oka, M. Sulfasalazine in early rheumatoid arthritis. A 48-week double-blind, prospective, 
placebo-controlled study. Arthritis and rheumatism 36, 1501–1509 (1993).
 50. Stone, M., Fortin, P. R., Pacheco-Tena, C. & Inman, R. D. Should tetracycline treatment be used more extensively for rheumatoid 
arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. The Journal of rheumatology 30, 2112–2122 
(2003).
 51. Morton, A. M. et al. Endoscopic photoconversion reveals unexpectedly broad leukocyte trafficking to and from the gut. Proc Natl 
Acad Sci USA 111, 6696–6701 (2014).
 52. Hwang, Y. G. et al. Differential response of serum amyloid A to different therapies in early rheumatoid arthritis and its potential value 
as a disease activity biomarker. Arthritis research & therapy 18, 108 (2016).
 53. Gabay, C. et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or 
adalimumab in patients with rheumatoid arthritis. Annals of the rheumatic diseases 75, 1806–1812 (2016).
 54. Migita, K. et al. Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for 
rheumatoid arthritis. Clinical and experimental immunology 175, 208–214 (2014).
 55. Shen, C. et al. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in 
patients with rheumatoid arthritis. Molecular medicine reports 11, 1528–1534 (2015).
 56. Targonska-Stepniak, B. & Majdan, M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular 
and renal involvement in patients with rheumatoid arthritis. Mediators of inflammation 2014, 793628 (2014).
 57. Hong, C. et al. An involvement of SR-B1 mediated p38 MAPK signaling pathway in serum amyloid A-induced angiogenesis in 
rheumatoid arthritis. Molecular immunology 66, 340–345 (2015).
 58. Connolly, M. et al. Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. 
Annals of the rheumatic diseases 75, 1392–1398 (2016).
 59. da Rocha, L. F. Jr. et al. Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity. The 
Journal of rheumatology 39, 1320–1325 (2012).
 60. Ikeuchi, H. et al. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis and 
rheumatism 52, 1037–1046 (2005).
 61. Leipe, J. et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Annals of the 
rheumatic diseases 70, 1453–1457 (2011).
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7: 15613  | DOI:10.1038/s41598-017-15802-x
 62. Benham, H. et al. Th17 and Th22 cells in psoriatic arthritis and psoriasis. Arthritis research & therapy 15, R136 (2013).
 63. Block, K. E., Zheng, Z., Dent, A. L., Kee, B. L. & Huang, H. Gut Microbiota Regulates K/BxN Autoimmune Arthritis through 
Follicular Helper T but Not Th17 Cells. Journal of immunology (Baltimore, Md.: 1950) 196, 1550–1557 (2016).
 64. Jacobs, J. P., Wu, H. J., Benoist, C. & Mathis, D. IL-17-producing T cells can augment autoantibody-induced arthritis. Proc Natl Acad 
Sci USA 106, 21789–21794 (2009).
 65. Shi, G. et al. Phenotype switching by inflammation-inducing polarized Th17 cells, but not by Th1 cells. Journal of immunology 
(Baltimore, Md.: 1950) 181, 7205–7213 (2008).
 66. Basdeo, S. A. et al. Ex-Th17 (Nonclassical Th1) Cells Are Functionally Distinct from Classical Th1 and Th17 Cells and Are Not 
Constrained by Regulatory T Cells. Journal of immunology (Baltimore, Md.: 1950) 198, 2249–2259 (2017).
 67. Leipe, J. et al. Role of Th17 cells in human autoimmune arthritis. Arthritis and rheumatism 62, 2876–2885 (2010).
 68. Colin, E. M. et al. 1,25-dihydroxyvitamin D3 modulates Th17 polarization and interleukin-22 expression by memory T cells from 
patients with early rheumatoid arthritis. Arthritis and rheumatism 62, 132–142 (2010).
 69. van Hamburg, J. P. et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix 
metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A 
production. Arthritis and rheumatism 63, 73–83 (2011).
 70. van Hamburg, J. P. et al. IL-17/Th17 mediated synovial inflammation is IL-22 independent. Annals of the rheumatic diseases 72, 
1700–1707 (2013).
 71. Yamada, H. et al. Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. Annals of the rheumatic 
diseases 67, 1299–1304 (2008).
 72. Miao, J. et al. Frequencies of circulating IL-17-producing CD4 + CD161 + T cells and CD4 + CD161 + T cells correlate with disease 
activity in rheumatoid arthritis. Modern rheumatology 24, 265–570 (2014).
 73. Chalan, P. et al. Circulating CD4 + CD161 + T lymphocytes are increased in seropositive arthralgia patients but decreased in 
patients with newly diagnosed rheumatoid arthritis. PloS one 8, e79370 (2013).
 74. Jandus, C. et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. 
Arthritis and rheumatism 58, 2307–2317 (2008).
 75. Raychaudhuri, S. K., Saxena, A. & Raychaudhuri, S. P. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial 
spondyloarthritis. Clinical rheumatology 34, 1019–1023 (2015).
 76. Joosten, L. A., Helsen, M. M., van de Loo, F. A. & van den Berg, W. B. Anticytokine treatment of established type II collagen-induced 
arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis and rheumatism 39, 
797–809 (1996).
 77. Scher, J. U. et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 4, 60 (2016).
 78. McDonald, D. et al. An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and 
archaea. The ISME journal 6, 610–618 (2012).
 79. Abdollahi-Roodsaz, S. et al. Toll-like receptor 2 controls acute immune complex-driven arthritis in mice by regulating the inhibitory 
Fcgamma receptor IIB. Arthritis and rheumatism 65, 2583–2593 (2013).
 80. Abdollahi-Roodsaz, S. et al. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. 
Arthritis and rheumatism 56, 2957–2967 (2007).
Acknowledgements
This study was supported by the Netherlands Organization for Scientific Research (VENI 916.12.039), the Dutch 
Arthritis Foundation (AFS 14-1-291 and 16-1-403), and the Arthritis National Research Foundation (ANRF 15-
A0-00-004310-01) grants to Dr. Abdollahi and the European BTCure Grant No. 115142-2. The study was further 
supported by Grant No. K23AR064318 from NIAMS to Dr. Scher, The Colton Center for Autoimmunity (Scher 
and Abdollahi), and The Riley Family Foundation (Scher and Abdollahi).
Author Contributions
R.R., H.E.-M., P.M.K., F.A.L., P.L.L.,W.B.B., M.I.K., J.U.S. and S.A.-R. designed the study; R.R., H.E.-M., B.W., 
M.H., L.B., S.A.-R. performed the experiments. R.R., H.E.-M., J.M., J.U.S., S.A.-R. acquired, analyzed and 
interpreted the data; R.R. and S.A.-R. drafted the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15802-x.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
